These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29633507)

  • 1. A randomised, placebo-controlled, multicentre, Phase 2 clinical trial to evaluate the efficacy and safety of GV1001 in patients with benign prostatic hyperplasia.
    Moon KT; Yoo TK; Kwon SY; Ha JY; Byun SS; Kim JH; Chung JI; Kim TH; Moon HS; Kim SJ; Lee KS
    BJU Int; 2018 Aug; 122(2):283-292. PubMed ID: 29633507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Singh DV; Mete UK; Mandal AK; Singh SK
    J Sex Med; 2014 Jan; 11(1):187-96. PubMed ID: 24165272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies.
    Oelke M; Wagg A; Takita Y; Büttner H; Viktrup L
    BJU Int; 2017 May; 119(5):793-803. PubMed ID: 27988986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
    Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
    BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
    J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia.
    Debruyne F; Gres AA; Arustamov DL
    Eur Urol; 2008 Jul; 54(1):170-7. PubMed ID: 18417275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Medium-to-long-term Use of Tolterodine Extended Release with or without Tamsulosin in Patients with Benign Prostate Hyperplasia and Larger Prostate Size: A Double-blind, Placebo-controlled, Randomized Clinical Trial.
    Cai JL; Zhou Z; Yang Y; Yan YF; Jing S; Na YQ
    Chin Med J (Engl); 2016 Dec; 129(24):2899-2906. PubMed ID: 27958220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
    Egerdie RB; Auerbach S; Roehrborn CG; Costa P; Garza MS; Esler AL; Wong DG; Secrest RJ
    J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia.
    Tamimi NA; Mincik I; Haughie S; Lamb J; Crossland A; Ellis P
    BJU Int; 2010 Sep; 106(5):674-80. PubMed ID: 20184577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L
    Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
    Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
    Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P; Kirby RS
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():83-92. PubMed ID: 15700491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials.
    Mulhall JP; Brock GB; Glina S; Baygani S; Donatucci CF; Maggi M
    J Sex Med; 2016 May; 13(5):843-51. PubMed ID: 27017071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled study.
    Zhang Z; Li H; Zhang X; Dai Y; Park HJ; Jiann BP; Li P; Lou Y; Ye Z; Viktrup L
    Int J Urol; 2019 Feb; 26(2):192-200. PubMed ID: 30362173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies.
    Porst H; Oelke M; Goldfischer ER; Cox D; Watts S; Dey D; Viktrup L
    Urology; 2013 Sep; 82(3):667-73. PubMed ID: 23876588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
    Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
    J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia.
    Kirby RS; Andersen M; Gratzke P; Dahlstrand C; Høye K
    BJU Int; 2001 Feb; 87(3):192-200. PubMed ID: 11167641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.